It has been a volatile year for the biotech.

Pfizer (NYSE:PFE) and its German partner BioNTech (BNTX) disclosed Phase 2/3 data on Saturday to indicate that the companies’ Omicron-adapted vaccine candidates generated a stronger immune response ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

Pfizer and its German partner BioNTech are ending a clinical trial they agreed to run in 2025 when receiving approval from U.S. authorities for their updated COVID-19 immunization. A BioNTech ...

Pfizer PFE will announce its third-quarter 2026 earnings on Nov. 3, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

Moderna is suing its chief competitor in the COVID-19 vaccine space, alleging that Pfizer and BioNTech stole key technology used in the development of that group's inoculation. Both Moderna and the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Exclusive-Pfizer, BioNTech Halt US COVID Vaccine Study After Recruitment Struggles By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of ⁠their ...